Foghorn Therapeutics Inc. · NASDAQ:FHTX

Foghorn Therapeutics — AACR Annual Meeting 2024

24 slides from Foghorn Therapeutics's conference presentation, April 2024

  1. Slide 1: Targeted Protein Degradation and The Chromatin Regulatory System

    Targeted Protein Degradation and The ​ Chromatin Regulatory System Steven Bellon, Ph.D. Foghorn Therapeutics, Cambridge MA 1

  2. Slide 2: Foghorn Research is Focused on Chromatin Biology

    Foghorn Research is Focused on Chromatin Biology Dysregulated chromatin underlies oncogenesis Brd9 FHD- FHD- 286 909 BAF complex: Gene expression in the right Bromodomains (Brm/Brg1, Brm sel, (CBP, EP300) cells at the right time is critical ARID1B) for normal growth, development, and homeostasis 2

  3. Slide 3: Broad Pipeline Across a Range of Targets and Modalities

    Broad Pipeline Across a Range of Targets and Modalities Modality Program Disease Discovery Phase 1 Phase 2 Phase 3 Commercial Rights FHD-286 (BRG1/BRM) Relapsed/Refractory AML Enzyme Inhibitors FHD-909 (Selective BRG1 mutant cancers (e.g., ~8-10% of NSCLC, bladder, BRM) endometrial, colorectal) BRG1

  4. Slide 4: CBP and EP300 Proteins… A Decades Long Challenge in Selectivity

    CBP and EP300 Proteins… A Decades Long Challenge in Selectivity CBP and EP300 have multiple conserved domains, thus achieving selectivity with a small molecule is a significant challenge • CBP and EP300 are chromatin regulators and histone acetyltransferases • EP300/CBP regulate protein abundance th

  5. Slide 5: Genentech and Cellcentric Have Reported Significant, but Reversible, Thrombocytopenia

    Genentech and Cellcentric Have Reported Significant, but Reversible, Thrombocytopenia for Their Dual CBP/EP300 Bromodomain Inhibitors Genentech Cellcentric Katavolos et al., Toxicol Pathol, 2020 5

  6. Slide 6: Selective Degradation of CBP to Address Mutant EP300 Cancers

    Selective Degradation of CBP to Address Mutant EP300 Cancers • CBP Selective Degrader Poster (D. Sappal): Session: Tuesday, April 9, 1:30pm–5pm; 6067 / 26 • Long-Acting Injectable Platform Poster (M. Lin): Session: Wednesday, April 10, 9am–12:30pm; 7185 / 26 6

  7. Slide 7: A CBP Selective Degrader Could Address Up To 100K+ Patients Annually

    A A CBP CBP Selective Selective Degrader Could Address Degrader Could Address Up Up To To 100K+ 100K+ Patients Annually Across Multiple Tumor Types EP300 Mutant Cancers Large Addressable Population (G7) • 100K+ patients annually* • Identification via existing diagnostic tests Additional opportunitie

  8. Slide 8: CBP Selective Degrader Evolution Has Yielded Fast Kinetics and Complete Degradation

    CBP Selective Degrader Evolution Has Yielded Fast Kinetics, and Complete Target Degradation with Selectivity Over EP300 dCBP-1 dCBP-7 dCBP-4 dCBP-5 dCBP-10 CBP EP300 Max Rate 0.4 0.6 0.7 1.1 2.2 Dmax 75% 90% 95% 90% 98% 8

  9. Slide 9: Enhancing Selective CBP Degradation While Reducing Bromodomain Binding

    Enhancing Selective CBP Degradation While Significantly Reducing CBP/EP300 Bromodomain Binding POTENT & SELECTIVE TARGET ZONE • Established robust SAR to significantly TR-FRET EP300 IC50 (µM, non-cell based) reduce CBP & EP300 bromodomain binding affinities while enhancing selective CBP degradation

  10. Slide 10: Advanced CBP Selective Degraders Validate Synthetic Lethal Hypothesis

    Advanced CBP Selective Degraders Validate Synthetic Lethal Hypothesis Across EP300mut Cell Lines Colorectal Gastric Bladder Lung 150 150 150 RKO 150 639V AGS LU99 HT29 UM-UC-3 NCI-H1648 % Cell Viability % Cell Viability IM95 % Cell Viability % Cell Viability 100 100 100 100 50 50 50 50 0 0 0 0 01 00

  11. Slide 11: Selective CBP Degradation Results in Significant Tumor Growth Inhibition

    Selective CBP Protein Degradation Results in Significant Tumor Growth Inhibition in Colorectal and Bladder EP300 Null Models COLORECTAL BLADDER RKO (EP300 Null) Model 639V (EP300 Null) Model 2,500 3,000 Vehicle Control Vehicle (BID) Tumor Volume (mm³ + SEM) Tumor Volume (mm³ + SEM) 2,500 2,000 FHT-C

  12. Slide 12: Selective CBP Protein Degradation Results in Tumor Regression in Gastric Model

    Selective CBP Protein Degradation Results in Tumor Regression in Gastric EP300 Null Model GASTRIC AGS (EP300 Null) Model 1,500 Vehicle (BID) Tumor Volume (mm³ + SEM) FHT-CBPd-59, 10mg/kg (QD) FHT-CBPd-59, 3mg/kg (QD) FHT-CBPd-59, 1mg/kg (QD) 1,000 FHT-CBPd-59, 0.3mg/kg (QD) FHT-CBPd-59, 0.1mg/kg (QD

  13. Slide 13: Long-Acting Injectable Formulations Provide Weeks of Sustained PK and CBP Degradation

    Long-Acting Injectable Formulations Provide 2 Weeks of Sustained PK and CBP Degradation From a Single Dose (sc or im) 2-week PK/PD study in RKO tumor-bearing mice dCBP-59 PK/PD (60mg/kg, sc) dCBP-59 PK/PD (150mg/kg, sc) dCBP-59 PK/PD (150mg/kg, im) dCBP-9 PK/PD (150mg/kg, s.c) dCBP-9 PK/PD (150mg/kg

  14. Slide 14: Selective CBP Degraders Do Not Show Thrombocytopenia at Efficacious Doses

    In Contrast to Competitor Compounds, Selective CBP Degraders Do Not Show Thrombocytopenia at Efficacious Doses • Selective CBP degradation has no impact on platelet count 1500 following 14-days of dosing in an investigational safety Platelets (x109 cells/L) study in mice 1000 • Dual CBP/EP300 inhibi

  15. Slide 15: CBP Selective Degrader Spares Megakaryocytes In Vivo

    CBP Selective Degrader Spares Megakaryocytes In Vivo GNE781 (dual BDi) CBP Selective Degraders • Internally validated observation of decreased • To date, we have not observed thrombocytopenia platelet counts at efficacious doses/exposures with any of our CBP degraders • Dual CBP/EP300 degradation re

  16. Slide 16: Selective Degradation of EP300 to Address CBP Mutation and EP300 Dependent Cancers

    Selective Degradation of EP300 to Address CBP Mutation and EP300 Dependent Cancers • EP300 Selective Degrader Poster (M. Zimmerman): Session: Tuesday, April 9, 1:30pm-5pm; 6064 / 23 16

  17. Slide 17: An EP300 Selective Degrader Would Address 100K+ Patients Annually

    An EP300 Selective Degrader Would Address 100K+ Patients Annually Across Solid Tumors and Heme Malignancies CBP Mutant Tumors + EP300 Dependent Cancers Large Addressable Population (G7) • 100K+ patients annually* • Identification via existing diagnostic tests Additional opportunities include EP300-d

  18. Slide 18: Improving Rate and Depth of Degradation as We Advance EP300 Selective Chemical Matter

    Improving Rate and Depth of Degradation as We Advance EP300 Selective Chemical Matter dEP300-2 dEP300-9 dEP300-1 dEP300-6 EP300 CBP Max Rate 0.4 0.3 0.35 0.75 Dmax 80% 80% 92% 94% 18

  19. Slide 19: EP300 Biased Degradation Attenuates Proliferation of AR+ Prostate Lines

    EP300 Biased Degradation Attenuates Proliferation of AR+ Prostate Lines and Blocked DHT Induced PSA Induction in VCAP Prostate Model 14-day cell growth dEP300-2 DMSO (50 nM) 24 24 10nM DHT (hr): 0 4 0 4 ACTB KLK3 (PSA) KRT8 VCAP (AR+) dEP300-2 • EP300 biased degradation by dEP300-2 has a cell killin

  20. Slide 20: mRNA Sequencing Shows dEP300-2 Attenuates AR-signaling in VCAP Cells

    mRNA Sequencing Demonstrates That dEP300-2 Attenuates AR-signaling in VCAP Cells Both In Vitro And In Vivo dEP300-2 TREATMENT ATTENUATES AR-DRIVEN TRANSCRIPTION dEP300-2 BLOCKS THE UPREGULATION OF AR TARGETS IN VCAP IN VCAP XENOGRAFT TUMORS CELLS FOLLOWING DHT STIMULATION VCAP (partially castration-

  21. Slide 21: In Vivo POC: EP300 Degradation Results in Significant Tumor Growth Inhibition

    In Vivo POC: EP300 Degradation Results in Significant Tumor Growth Inhibition in AR+ VCaP Prostate Model and Positively Differentiates from Enzalutamide VCAP (AR+) Prostate CDX Model 2000 Vehicle, sc, BID x 5wks Enzalutamide, po, 30mg/kg, QD x 5wks (TGI=29%) dEP300-2, sc, FHT-72332, sc,50 mg/kg, BID

  22. Slide 22: EP300 Dependency in Hematological Malignancies

    EP300 Dependency in Hematological Malignancies (DLBCL) Vehicle dEP300-2 (10 mg/kg BID) dEP300-2 (20 mg/kg BID) dEP300-2 (50 mg/kg BID) • Additional in vitro anti-proliferation studies are ongoing in AML and other NHL/B-cell malignancies • Considering an in vitro PDX screen across B-cell heme maligna

  23. Slide 23: EP300 Degraders Do Not Show Thrombocytopenia at Efficacious Doses

    EP300 Degraders Docells/L) PLT (x10 Not Show Thrombocytopenia at 9 Efficacious Doses 2000 Platelets (x109 cells/L) 15002000 Platelets (x109 cells/L) 1500 • At efficacious doses, our EP300 degrader shows no 1000 reductions in platelet count following 14-days of 1000 dosing in an investigational safet

  24. Slide 24: Disclosure Information

    Disclosure Information Steven Bellon I have the following relevant financial relationships to disclose: Employee and stockholder and option holder of Foghorn Therapeutics Inc. 24

Foghorn Therapeutics — AACR Annual Meeting 2024 on 6ix